Prevention of Transition From Incipient to Overt Nephropathy With Telmisartan in Patients With Type 2 Diabetes
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
To date, evidence for long-term renoprotection with angiotensin receptor blockers (ARBs) has come almost exclusively from Caucasian patients (1–3), despite Japanese people being at high risk of diabetic nephropathy and very susceptible to end-stage renal disease (4–6). We conducted the INNOVATION Study (Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy) to evaluate the efficacy of an ARB in preventing transition from microalbuminuria to overt nephropathy in Japanese patients (7). This study is the first large-scale clinical study to investigate prevention of overt diabetic nephropathy using an ARB in normotensive and hypertensive Japanese patients with type 2 diabetes. The randomized, multicenter, double-blind, placebo-controlled trial was performed in patients aged from 30 to 74 years with type 2 diabetes and urinary albumin-to-creatinine ratio (UACR) 100–300 mg/g and serum creatinine <1.5 mg/dl (men) and <1.3 mg/dl (women). Exclusion criteria included type 1 diabetes, age of diabetes onset <30 years, seated systolic blood pressure (SBP)/diastolic blood pressure (DBP) ≥180/100 mmHg, and definable chronic kidney disease …
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In this trial, telmisartan also signi fi cantly reduced blood pressure levels.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [12]
In the citing paper
“In the INNOVATION trial, the ARB telmisartan was associated with a lower transition rate to overt nephropathy than placebo after 1 year of follow-up.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [12]
In the citing paper
“suggesting that use of RAS blockade may be bene fi cial in patients without hypertension. 12,14”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [12]
In the citing paper
“However, after adjustment for the difference in blood pressure levels between the placebo and treatment groups, the bene fi cial effect of telmisartan in delaying progression to overt nephropathy persisted.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [12]
In the citing paper
“The CREDENCE, DAPA-CKD, and EMPA-KIDNEY placebo-controlled trials were all stopped early for efficacy while testing canagliflozin, dapagliflozin, and empagliflozin, respectively.153,543,711”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [711]
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Parving, H., Lehnert, H., Brøchner‐Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · PubMed · Cited by 2,535
Progression, remission, regression of chronic renal diseases
Ruggenenti, P., Schieppati, A., & Remuzzi, G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04728-0 · Cited by 554
An Overview of Regular Dialysis Treatment in Japan (as of 31 December 2001)1
Patient Registration Committee, J. S. F. D. T. (2004) · Therapeutic Apheresis and Dialysis · doi:10.1111/j.1526-0968.2004.00109.x · Cited by 68
Makino, H., Haneda, M., Babazono, T., Moriya, T., Ito, S., Iwamoto, Y., Kawamori, R., Takeuchi, M., & Katayama, S. (2005) · Journal of International Medical Research · doi:10.1177/147323000503300610 · Cited by 32
Self-citationHollenberg, N. K. (2001) · Current Hypertension Reports · doi:10.1007/s11906-001-0035-5 · Cited by 8
Cited by
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
Self-citation2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
on behalf of The Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension, Ogihara, T., Kikuchi, K., Matsuoka, H., Fujita, T., Higaki, J., Horiuchi, M., Imai, Y., Imaizumi, T., Ito, S., et al. (2014) · Hypertension Research · doi:10.1038/hr.2014.68 · Cited by 1,385
Self-citationKDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Selby, N. M., & Taal, M. W. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14007 · Cited by 764
Japanese clinical practice guideline for diabetes 2019
Araki, E., Goto, A., Kondo, T., Noda, M., Noto, H., Origasa, H., Osawa, H., Taguchi, A., Tanizawa, Y., Tobe, K., et al. (2020) · Diabetology International · doi:10.1007/s13340-020-00439-5 · Cited by 545
Trajectories of kidney function in diabetes: a clinicopathological update
Oshima, M., Shimizu, M., Yamanouchi, M., Toyama, T., Hara, A., Furuichi, K., & Wada, T. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00462-y · Cited by 346
Japanese Clinical Practice Guideline for Diabetes 2019
Araki, E., Goto, A., Kondo, T., Noda, M., Noto, H., Origasa, H., Osawa, H., Taguchi, A., Tanizawa, Y., Tobe, K., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13306 · Cited by 341
Japanese Clinical Practice Guideline for Diabetes 2016
Haneda, M., Noda, M., Origasa, H., Noto, H., Yabe, D., Fujita, Y., Goto, A., Kondo, T., & Araki, E. (2018) · Diabetology International · doi:10.1007/s13340-018-0345-3 · Cited by 319
Self-citationDiabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes
Molitch, M. E., Adler, A. I., Flyvbjerg, A., Nelson, R. G., So, W.-Y., Wanner, C., Kasiske, B. L., Wheeler, D. C., de Zeeuw, D., & Mogensen, C. E. (2015) · Kidney International · doi:10.1038/ki.2014.128 · Cited by 268
Juusola, J. L. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-8-201204170-00004 · Cited by 244
Treatment of Diabetic Kidney Disease: Current and Future
Yamazaki, T., Mimura, I., Tanaka, T., & Nangaku, M. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0217 · Cited by 237
for the ORIENT study investigators, Imai, E., Chan, J. C. N., Ito, S., Yamasaki, T., Kobayashi, F., Haneda, M., & Makino, H. (2011) · Diabetologia · doi:10.1007/s00125-011-2325-z · Cited by 236
Self-citationIto, S., Kashihara, N., Shikata, K., Nangaku, M., Wada, T., Okuda, Y., & Sawanobori, T. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06870520 · Cited by 234
Self-citationJapanese Clinical Practice Guideline for Diabetes 2016
Haneda, M., Noda, M., Origasa, H., Noto, H., Yabe, D., Fujita, Y., Goto, A., Kondo, T., & Araki, E. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12810 · Cited by 181
Self-citationBakris, G., Burgess, E., Weir, M., Davidai, G., & Koval, S. (2008) · Kidney International · doi:10.1038/ki.2008.204 · Cited by 162
The effect of RAAS blockade on the progression of diabetic nephropathy
Roscioni, S. S., Heerspink, H. J. L., & de Zeeuw, D. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.251 · Cited by 162
Hypertension with diabetes mellitus complications
Yamazaki, D., Hitomi, H., & Nishiyama, A. (2018) · Hypertension Research · doi:10.1038/s41440-017-0008-y · Cited by 188
Evidence-based practice guideline for the treatment for diabetes in Japan 2013
Tajima, N., Noda, M., Origasa, H., Noto, H., Yabe, D., Fujita, Y., Goto, A., Fujimoto, K., Sakamoto, M., & Haneda, M. (2015) · Diabetology International · doi:10.1007/s13340-015-0206-2 · Cited by 154
Self-citationFink, H. A., Ishani, A., Taylor, B. C., Greer, N. L., MacDonald, R., Rossini, D., Sadiq, S., Lankireddy, S., Kane, R. L., & Wilt, T. J. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-8-201204170-00008 · Cited by 180
Alter, M., Ott, I. M., von Websky, K., Tsuprykov, O., Sharkovska, Y., Relle, K., Raila, J., Henze, A., Klein, T., & Hocher, B. (2012) · Kidney & Blood Pressure Research · doi:10.1159/000341487 · Cited by 156
Katayama, S., Yamada, D., Nakayama, M., Yamada, T., Myoishi, M., Kato, M., Nowack, C., Kolkhof, P., & Yamasaki, Y. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.11.021 · Cited by 132
Self-citationNishiyama, A., Konishi, Y., Ohashi, N., Morikawa, T., Urushihara, M., Maeda, I., Hamada, M., Kishida, M., Hitomi, H., Shirahashi, N., et al. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq371 · Cited by 132
Evidence-based Practice Guideline for the Treatment of CKD
(2009) · Clinical and Experimental Nephrology · doi:10.1007/s10157-009-0237-8 · Cited by 129
Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation
Raimondo, D. D., Tuttolomondo, A., Buttà, C., Miceli, S., Licata, G., & Pinto, A. V. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802481282 · Cited by 135
Cardiovascular disease in patients with chronic kidney disease
Hutchison, A. J. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s6206 · Cited by 149
O’Hare, A. M., Kaufman, J. S., Covinsky, K. E., Landefeld, C. S., McFarland, L. V., & Larson, E. B. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-10-200905190-00010 · Cited by 118
Maione, A., Navaneethan, S. D., Graziano, G., Mitchell, R. L., Johnson, D. W., Mann, J. F. E., Gao, P., Craig, J. C., Tognoni, G., Perkovic, V., et al. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq792 · Cited by 122
Renin–Angiotensin System Blockade and Cardiovascular and Renal Protection
Hoogwerf, B. J. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.10.009 · Cited by 104
Herrington, W. G., Judge, P. K., Grams, M. E., & Wanner, C. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01942-7 · Cited by 150
Slinin, Y., Ishani, A., Rector, T., Fitzgerald, P., MacDonald, R., Tacklind, J., Rutks, I., & Wilt, T. J. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.017 · Cited by 99
Wada, T., Inagaki, M., Yoshinari, T., Terata, R., Totsuka, N., Gotou, M., & Hashimoto, G. (2021) · Clinical and Experimental Nephrology · doi:10.1007/s10157-020-01963-z · Cited by 97
Angiotensin II Blockade and Renal Protection
Kobori, H., Mori, H., Masaki, T., & Nishiyama, A. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319170009 · Cited by 110
Galle, J., Schwedhelm, E., Pinnetti, S., Böger, R. H., Wanner, C., & on behalf of the VIVALDI investigators (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn230 · Cited by 105
Fujita, H., Taniai, H., Murayama, H., Ohshiro, H., Hayashi, H., Sato, S., Kikuchi, N., Komatsu, T., Komatsu, K., Komatsu, K., et al. (2013) · Endocrine Journal · doi:10.1507/endocrj.ej13-0305 · Cited by 95
Xu, H., Wang, X.-T., Cheng, Y., Zhao, J., Zhou, Y.-J., Yang, J., & Qi, M.-Y. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.06.055 · Cited by 87
Screening, identifying, and treating chronic kidney disease: why, who, when, how, and what?
Farrell, D. R., & Vassalotti, J. A. (2024) · BMC Nephrology · doi:10.1186/s12882-024-03466-5 · Cited by 110
TNF-αand Microalbuminuria in Patients with Type 2 Diabetes Mellitus
Lampropoulou, I.-T., Stangou, M. J., Papagianni, A. A., Didangelos, T., Iliadis, F. S., & Efstratiadis, G. (2014) · Journal of Diabetes Research · doi:10.1155/2014/394206 · Cited by 81
Makino, H., Haneda, M., Babazono, T., Moriya, T., Ito, S., Iwamoto, Y., Kawamori, R., Takeuchi, M., & Katayama, S. (2008) · Hypertension Research · doi:10.1291/hypres.31.657 · Cited by 74
Self-citationSchievink, B., Kröpelin, T. F., Mulder, S., Parving, H. ‐., Remuzzi, G., Dwyer, J. P., Vemer, P., de Zeeuw, D., & Heerspink, H. J. L. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12583 · Cited by 81
Antar, S. A., Abdo, W. S., Taha, R. S., Farage, A. E., EI-Moselhy, L. E., Amer, M. E., Monsef, A. S. A., Hamid, A. M. A., Kamel, E. M., Ahmeda, A. F., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120260 · Cited by 78
Leoncini, G., Viazzi, F. C., Cosmo, S. D., Russo, G. T., Fioretto, P., & Pontremoli, R. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00803-3 · Cited by 77
Telmisartan: A Different Angiotensin II Receptor Blocker Protecting a Different Population?
Burnier, M. (2009) · Journal of International Medical Research · doi:10.1177/147323000903700602 · Cited by 72
for the Japan Diabetes Complications Study Group, Katayama, S., Moriya, T., Tanaka, S., Tanaka, S., Yajima, Y., Sone, H., Iimuro, S., Ohashi, Y., Akanuma, Y., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-2025-0 · Cited by 67
Self-citationTelmisartan: just an antihypertensive agent? A literature review
Destro, M., Cagnoni, F., Dognini, G. P., Galimberti, V., Taietti, C., Cavalleri, C., & Galli, E. G. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.632367 · Cited by 65
Kato, S., Maruyama, S., Makino, H., Wada, J., Ogawa, D., Uzu, T., Araki, H., Koya, D., Kanasaki, K., Oiso, Y., et al. (2015) · Clinical and Experimental Nephrology · doi:10.1007/s10157-015-1106-2 · Cited by 61
Self-citationSuksomboon, N., Poolsup, N., & Prasit, T. (2011) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2011.01295.x · Cited by 63
Renin-Angiotensin-Aldosterone System Blockade in Diabetic Nephropathy. Present Evidences
Maneiro, L. L., & Puente-García, A. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4111908 · Cited by 61
Clinical therapeutic strategies for early stage of diabetic kidney disease
Kitada, M. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i3.342 · Cited by 55
Are There Effects of Renin–Angiotensin System Antagonists Beyond Blood Pressure Control?
Bakris, G. L. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.10.010 · Cited by 61
Moriya, T., Tanaka, S., Kawasaki, R., Ohashi, Y., Akanuma, Y., Yamada, N., Sone, H., Yamashita, H., Katayama, S., & for the Japan Diabetes Complications Study Group (2013) · Diabetes Care · doi:10.2337/dc12-2327 · Cited by 56
Self-citationMashitani, T., Hayashino, Y., Okamura, S., Tsujii, S., & Ishii, H. (2013) · Diabetes Care · doi:10.2337/dc13-0407 · Cited by 57
New standards in hypertension and cardiovascular risk management: focus on telmisartan
Galzerano, D., Capogrosso, C., Michele, S. D., Galzerano, A., Paparello, P., Lama, D., & Gaudio, C. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s7857 · Cited by 58
Kusunoki, H., Taniyama, Y., Azuma, J., Iekushi, K., Sanada, F., Otsu, R., Iwabayashi, M., Okayama, K., Rakugi, H., & Morishita, R. (2012) · Hypertension · doi:10.1161/hypertensionaha.111.176263 · Cited by 53
Heerspink, H. J. L., Persson, F., Brenner, B. M., Chaturvedi, N., Brunel, P., McMurray, J. J. V., Desai, A. S., Solomon, S. D., Pfeffer, M. A., PARVING, H.-H. D., et al. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00469-6 · Cited by 52
Cardiovascular disease in chronic kidney disease: risk factors, pathogenesis, and prevention.
Ardhanari, S., Alpert, M., & Aggarwal, K. B. (2014) · PubMed · Cited by 57
Renin-angiotensin-aldosterone system-mediated redox effects in chronic kidney disease
Nistala, R., Wei, Y., Sowers, J. R., & Whaley‐Connell, A. T. (2009) · Translational research · doi:10.1016/j.trsl.2008.12.008 · Cited by 46
Whaley‐Connell, A. T. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3121 · Cited by 46
Antihypertensive and Metabolic Effects of Telmisartan in Hypertensive HIV-Positive Patients
Vecchiet, J., Ucciferri, C., Falasca, K., Mancino, P., Iorio, A. D., & Caterina, R. D. (2011) · Antiviral Therapy · doi:10.3851/imp1809 · Cited by 45
Nishiyama, A., Nakagawa, T., Kobori, H., Nagai, Y., Okada, N., Konishi, Y., Morikawa, T., Okumura, M., Meda, I., Kiyomoto, H., et al. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283060efa · Cited by 47
Self-citationOtt, I. M., Alter, M., von Websky, K., Kretschmer, A., Tsuprykov, O., Sharkovska, Y., Relle, K., Raila, J., Henze, A., Stasch, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042623 · Cited by 43
Li, X., Lan, Y., Wang, Y., Nie, M.-H., Lu, Y., & Zhao, E. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6318 · Cited by 48
Farmer, A. A., Stevens, R., Hirst, J. A., Lung, T. W.-C., Oke, J. L., Clarke, P., Glasziou, P., Neil, A., Dunger, D. B., Colhoun, H. M., et al. (2014) · Health Technology Assessment · doi:10.3310/hta18140 · Cited by 44
Sofue, T., Kiyomoto, H., Kobori, H., Urushihara, M., Nishijima, Y., Kaifu, K., Hara, T., Matsumoto, S., Ichimura, A., Ohsaki, H., et al. (2012) · American Journal of Hypertension · doi:10.1038/ajh.2012.1 · Cited by 41
Self-citationAnti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity
Ayza, M. A., Zewdie, K. A., Tesfaye, B. A., Gebrekirstos, S. T., & Berhe, D. F. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s265399 · Cited by 45
Renal protection in diabetes: lessons from ONTARGET®
Ritz, E., Schmieder, R. E., & Pollock, C. A. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-60 · Cited by 40
Epigenetic modification in diabetic kidney disease
Liu, Z., Liu, J., Wang, W., An, X., Luo, L., Yu, D., & Sun, W. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1133970 · Cited by 43
Identification and Management of Albuminuria in the Primary Care Setting
Kuritzky, L., Toto, R. D., & Buren, P. N. V. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2010.00424.x · Cited by 39
Ruzicka, M., Quinn, R. R., McFarlane, P., Hemmelgarn, B. R., Prasad, G. V. R., Feber, J., NESRALLAH, G. E., MacKinnon, M., Tangri, N., McCormick, B. B., et al. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.03.003 · Cited by 36
Kelepouris, E., Peter, W. L. S., Neumiller, J. J., & Wright, E. E. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01416-2 · Cited by 45
Kario, K. (2015) · Pulse · doi:10.1159/000381300 · Cited by 34
Youn, J.-Y., Zhou, J. F., & Cai, H. “. (2015) · Molecular Endocrinology · doi:10.1210/me.2014-1313 · Cited by 32
Microalbuminuria and hypertension in HIV-infected patients: a preliminary study of telmisartan.
Ucciferri, C., Falasca, K., Mancino, P., Iorio, A. D., & Vecchiet, J. (2012) · PubMed · Cited by 34
Imai, E., Haneda, M., Yamasaki, T., Kobayashi, F., Harada, A., Ito, S., Chan, J. C. N., & Makino, H. (2013) · Hypertension Research · doi:10.1038/hr.2013.86 · Cited by 29
Self-citationTelmisartan Attenuates Diabetic Nephropathy by Suppressing Oxidative Stress in db/db Mice
Horiguchi, C. S., Ogawa, D., Wada, J., Tachibana, H., Kodera, R., Eguchi, J., Nakatsuka, A., Terami, N., Shikata, K., & Makino, H. (2013) · Nephron Experimental Nephrology · doi:10.1159/000343102 · Cited by 33
Self-citationRenal protection with angiotensin receptor blockers: where do we stand
Schmieder, R. E., Ruilope, L. M., & Barnett, A. H. (2011) · Journal of Nephrology · doi:10.5301/jn.2011.6445 · Cited by 31
Mallik, R., & Chowdhury, T. A. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221081601 · Cited by 31
Fujita, H., Sakamoto, T., Komatsu, K., Fujishima, H., Morii, T., Narita, T., Takahashi, T., & Yamada, Y. (2011) · Hypertension Research · doi:10.1038/hr.2011.127 · Cited by 29
Comparing angiotensin II receptor blockers on benefits beyond blood pressure
Siragy, H. M. (2010) · Advances in Therapy · doi:10.1007/s12325-010-0028-3 · Cited by 29
Measuring Albuminuria in Individuals With Obesity: Pitfalls of the Urinary Albumin-Creatinine Ratio
Chagnac, A., & Friedman, A. N. (2024) · Kidney Medicine · doi:10.1016/j.xkme.2024.100804 · Cited by 35
Effects of angiotensin II receptor blockers on diabetic nephropathy
Kalaitzidis, R., & Bakris, G. L. (2009) · Journal of Hypertension · doi:10.1097/01.hjh.0000357904.71080.7d · Cited by 28
Treatment and practical considerations of diabetic kidney disease
Bilen, Y., Almoushref, A., Alkwatli, K., Osman, O., Mehdi, A., & Sawaf, H. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1264497 · Cited by 29
Dual Renin-Angiotensin-Aldosterone System Blockade for Diabetic Kidney Disease
Pichler, R. H., & de Boer, I. H. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0126-2 · Cited by 26
ASIAN PACIFIC SOCIETY OF NEPHROLOGY CLINICAL PRACTICE GUIDELINE ON DIABETIC KIDNEY DISEASE
Liew, A., Bavanandan, S., Prasad, N., Wong, M. G., Chang, J. M., Eiam‐Ong, S., Hao, C., Lim, C. Y., Lim, S. K., Oh, K., et al. (2020) · Nephrology · doi:10.1111/nep.13785 · Cited by 24
Discontinuation of RAAS Inhibition in Children with Advanced CKD
van den Belt, S. M., Heerspink, H. J. L., Kirchner, M., Gracchi, V., Thurn‐Valsassina, D., Bayazıt, A. K., Niemirska, A., Canpolat, N., Bulut, İ. K., Ažukaitis, K., et al. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09750819 · Cited by 25
Zhang, Q., Xiao, X., Li, M., Li, W., Yu, M., Zhang, H., Sun, X., Mao, L., & Xiang, H. (2012) · Journal of Molecular Endocrinology · doi:10.1530/jme-12-0020 · Cited by 24
Wu, M., Lu, J., Zhang, L., Liu, F., Chen, S., Han, Y., Zhao, F., Guo, K., Bao, Y., Chen, H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21684 · Cited by 22
Agents in development for the treatment of diabetic nephropathy
Goh, S., Jasik, M., & Cooper, M. E. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.13.3.447 · Cited by 24
Cardiorenal syndrome and diabetes: an evil pairing
Méndez, A. B., Vergara, A., Olivella, A., Azancot, M. A., Soriano-Colomé, T., & Soler, M. J. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1185707 · Cited by 24
Kimura, T., Sanada, J., Shimoda, M., Hirukawa, H., Fushimi, Y., Nishioka, M., Kinoshita, T., Okauchi, S., Obata, A., Kohara, K., et al. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12774 · Cited by 21
Chapter 4: Blood pressure management in CKD ND patients with diabetes mellitus
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.54 · Cited by 23
Chapter 3: Blood pressure management in CKD ND patients without diabetes mellitus
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.53 · Cited by 21
Morikawa, A., Ishizeki, K., Iwashima, Y., Yokoyama, H., Muto, E., Oshima, E., SEKIGUCHI, M., Miura, T., Itoh, H., & Haneda, M. (2011) · Clinical and Experimental Nephrology · doi:10.1007/s10157-011-0512-3 · Cited by 22
Self-citationPalmer, B. F. (2007) · American Journal of Nephrology · doi:10.1159/000112270 · Cited by 20
Shetty, S., Suvarna, R., Awasthi, A., Bhojaraja, M. V., & Pappachan, J. M. (2025) · Diagnostics · doi:10.3390/diagnostics15080973 · Cited by 25
Natale, P., Palmer, S. C., Navaneethan, S. D., Craig, J. C., & Strippoli, G. F. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006257.pub2 · Cited by 37
Fujii, H., Kono, K., Nakai, K., Goto, S., Kitazawa, R., Fukagawa, M., & Nishi, S. (2014) · Nephron Extra · doi:10.1159/000358886 · Cited by 19
Sugiyama, T., Goryoda, S., Inoue, K., Ihana‐Sugiyama, N., & Nishi, N. (2017) · BMC Health Services Research · doi:10.1186/s12913-017-2784-0 · Cited by 19
Chazova, I. E., Shestakova, M. V., Zhernakova, Y. V., Blinova, N. V., Маркова, Т. Н., Mazurina, N. V., Владиславович, Е. М., Tereshchenko, S. N., Жиров, И. В., Komarov, A. L., et al. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-2-6-61 · Cited by 25
Metadata
- Authors
- Makino, H., Haneda, M., Babazono, T., Moriya, T., Ito, S., Iwamoto, Y., Kawamori, R., Takeuchi, M., Katayama, S., & for the INNOVATION Study Group
- Affiliations
- Okayama University (JP)
- Asahikawa Medical University (JP)
- Tokyo Women's Medical University (JP)
- Kitasato University (JP)
- Tohoku University (JP)
- Juntendo University (JP)
- Saitama Medical University (JP)
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2007-06-01
- Volume
- 30
- Issue
- 6
- Pages
- 1577-1578
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2140563977
- Cited by
- 230
- References
- 8
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 5 · 2023: 14 · 2022: 8 · 2021: 8 · 2020: 12 · 2019: 3 · 2018: 7 · 2017: 11 · 2016: 8 · 2015: 14 · 2014: 14 · 2013: 17 · 2012: 21
- FWCI
- 13.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Keywords
- telmisartan, angiotensin receptor blockers, diabetic nephropathy, type 2 diabetes, microalbuminuria, renal protection, Japanese patients, hypertension, albumin-creatinine ratio
- MeSH terms
- Telmisartan, Adult, Aged, Albuminuria, Angiotensin-Converting Enzyme Inhibitors, Benzimidazoles, Benzoates, Diabetic Nephropathies, Double-Blind Method, Humans, Middle Aged, Placebos
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.